Latest OriGene Technologies Inc. Stories
3000 Highly Validated Monoclonal Antibodies Made Against Native Protein Epitopes Expands OriGene's Antibody Portfolio to Over 7500 ROCKVILLE, Md., July 28, 2011 /PRNewswire-USNewswire/ -- OriGene Technologies, Inc.
Breakthrough Technology Enables High Throughput Screening of Antibodies Against 10,000 Human Proteins ROCKVILLE, Md., July 25, 2011 /PRNewswire/ -- OriGene Technologies, Inc., a gene-centric life sciences company known for its development of cDNA clones, human full length proteins, antibodies, and other molecular tools for multiplex research introduces its major breakthrough technology High-Density Protein Microarray Chip for the quality control of its (TrueMAB(TM)) monoclonal antibodies....
ROCKVILLE, Md., Jan. 20, 2011 /PRNewswire/ -- OriGene Technologies, Inc. has recently achieved a significant milestone in its quest for developing an assay for every human protein through the release of 1,500 mouse monoclonal antibodies under the TrueMAB brand.
ROCKVILLE, Md., Aug. 12 /PRNewswire/ -- OriGene Technologies, Inc., a gene-centric life sciences company, announces the acquisition of Blue Heron Biotechnology, a pioneer in the gene synthesis business since 1999.
ROCKVILLE, Md., June 3 /PRNewswire/ -- OriGene Technologies, Inc., a leading gene-centric life sciences company, has announced the first of its kind launch of over 5,000 heavy isotope labeled human proteins as internal standards for SRM/MRM (single reaction monitoring, multiple reaction monitoring) mass spectrometry analyses.
SAN FRANCISCO and ROCKVILLE, Md., May 28 /PRNewswire/ -- Hitachi Software Engineering America, Ltd. (Hitachi Software) and OriGene Technologies, Inc.
In the news release, OriGene Technologies, Inc. to Build the World's Largest TrueMAB(TM) Monoclonal Antibody Facility in Wuxi, China, issued 18-May-2010 by OriGene Technologies, Inc.
ROCKVILLE, Md., May 18 /PRNewswire/ -- OriGene Technologies, Inc. with the support of Wuxi Biopharmaceutical R&D Outsourcing Services Park (China), will build one of the largest and most sophisticated monoclonal antibody production centers in the world in Wuxi, China.
ROCKVILLE, Md., March 17 /PRNewswire/ -- OriGene Technologies, Inc., a leading gene-centric life sciences company, announced the completion of a $16 million Series B financing led by IDG-Accel, SBI & TH Venture Capital Enterprise, and Zero2IPO.
- A transitional zone between two communities containing the characteristic species of each.